Laser Therapy for Sexual Health in Breast Cancer Survivors Receiving Aromatase Inhibitors

In this randomized clinical trial of breast cancer survivors receiving aromatase inhibitors, vulvovaginal CLT provided no additional benefit for sexual or vaginal health at 12 months. Improvements in both groups likely reflected FLT adherence, trial participation, or contextual factors rather than laser efficacy. High-quality sham-controlled trials remain essential before routine implementation.

Corresponding Author: Inmaculada Alonso, MD, MSc, PhD, Breast Cancer Unit–Gynecology, Obstetrics and Neonatology Service, University Hospital Joan XXIII Institut d’Investigació Sanitària Pere Virgili, C/Dr Mallafré 4. 43007 Tarragona, Spain (ialonso.hj23.ics@gencat.cat).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.